Aardvark Therapeutics, Inc.

Stage 4 · Declining · week 4

As of Oct 22, 2026, Aardvark Therapeutics is in Stage 4, the downtrend phase, now in week 4 (since Sep 29, 2026). It closed at $3.95, 75.0% below its 52-week high and below its 200-day average, which is falling.

Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. More about the company

$3.95

-7.49% today

$86.4M · Micro cap

Market Neutral — Building

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is AARD early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2025-02-13 → 2026-10-22

S? 41w

S2 7w

S4 15w

S1 13w

2025-02-132026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S? 41w → S2 3w → S3 4w → S2 7w → S3 1w → S4 15w → S1 13w → S4 3w current

Total tracked: 88 weeks across 8 stage runs.

AARD among Biotechnology421st of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…421	AARDAardvark Therapeutics, Inc.	Stage 4 · wk 4	16	−29.0%

vs 52W High

-75.0%

$3.48 lo$15.82 hi

75.0% below 52W high, deep Stage 4 damage

In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.

Stage Maturity

Week 4

1w13w26w

Week 4, early Stage 4 decline

How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.

vs 200 DMA

-41.2%

200 DMA: $6.72 · sloping down

In Stage 4, the stock is below its 200-day average, the hallmark of a downtrend. Stage analysis waits for that to reverse before buying.

Rel Volume

9.52x

vs 50-day avg

High volume on down days in Stage 4 confirms institutional selling. Low-volume bounces are typical. They lack real buyers and are easy to mistake for reversals.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-29.0%

-37.5%

-26.4%

YTD

-70.1%

-67.0%

Scan Membership

Not in any current scan.

Recent Stage Timeline

2026-10-22S4

Wk 4 · Vol 9.52x

2026-10-21S4

Wk 4 · Vol 1.59x

2026-10-20S4

Wk 4 · Vol 0.51x

2026-10-19S4

Wk 3 · Vol 0.99x

2026-10-16S4

Wk 3 · Vol 0.75x

2026-10-15S4

Wk 3 · Vol 0.52x

2026-10-14S4

Wk 3 · Vol 0.95x

2026-10-13S4

Wk 3 · Vol 1.67x

2026-10-12S4

Wk 2 · Vol 0.77x

2026-10-09S4

Wk 2 · Vol 1.08x

2026-10-08S4

Wk 2 · Vol 2.48x

2026-10-07S4

Wk 2 · Vol 1.70x

Moving averages & range

50 DMA

$5.38

200 DMA

$6.72

52W High

$15.82

52W Low

$3.48

5D Low

$3.74

Resistance levels (recent highs)

20d High

$5.35

60d High

$7.90

120d High

$7.90

250d High

$15.82

Next resistance

+35.4%

to 20d High

ROE

-66.0%

Profit margin 0.0%

Dividend Yield

0.00%

P/B 1.2

Aardvark Therapeutics: quick answers

What stage is Aardvark Therapeutics in?

As of Oct 22, 2026, Aardvark Therapeutics (AARD) is in Stage 4, the downtrend phase. It entered Stage 4 on Sep 29, 2026 and is in week 4. What the four stages mean

Is Aardvark Therapeutics in an uptrend?

No. Aardvark Therapeutics is in a Stage 4 downtrend. It trades 41.2% below its 200-day average, which is falling.

How far is Aardvark Therapeutics from its 52-week high?

Aardvark Therapeutics closed at $3.95 on Oct 22, 2026, 75.0% below its 52-week high of $15.82. Its 52-week low is $3.48.

How has Aardvark Therapeutics performed over the past year?

As of Oct 22, 2026, Aardvark Therapeutics is down 67.0% over the past year and down 70.1% so far in 2026.

Which sector and industry is Aardvark Therapeutics in?

Aardvark Therapeutics is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.